FDA 510(k) Clearances: Tracking, Timelines, and Decision Data

Track FDA 510(k) clearances, understand review timelines, interpret SE/NSE decisions, use the 510(k) database, and apply clearance statistics to your 2026 regulatory strategy.

Why 510(k) Clearance Data Matters for Your Strategy

Every 510(k) decision FDA makes is public. The clearance database contains decades of information about which devices were cleared, what predicates were used, how long review took, and what outcomes resulted. For manufacturers preparing a submission, this data answers the questions that determine your go-to-market timeline: How long will review actually take? What is the clearance rate for my device type? Which predicates did competitors use? What deficiencies does FDA cite most often?

This guide explains how to find, read, and strategically use 510(k) clearance data — going beyond the basic database search to show how clearance timelines, success rates, and decision patterns should inform your regulatory planning.

Understanding the 510(k) Decision Process

What "Clearance" Means

When FDA "clears" a 510(k), it issues a finding of Substantial Equivalence (SE). This means the new device is as safe and effective as a legally marketed predicate device. "Clearance" and "approval" are not the same thing in FDA terminology:

510(k) Clearance (SE): Device is substantially equivalent to a predicate. Most Class II devices.
PMA Approval: Device is demonstrated to be safe and effective through comprehensive evidence. Class III devices.
De Novo Grant: New classification established for a novel low-to-moderate risk device.

The distinction matters because FDA's standard of evidence differs between pathways. A 510(k) does not require proof of safety and effectiveness de novo — it requires proof of equivalence.

510(k) Decision Outcomes

FDA issues one of several decision types for each 510(k):

Decision Code	Meaning	Implication
SE	Substantially Equivalent	Device may be marketed in the US
SE with Limitations (SESU)	Substantially Equivalent subject to limitations	Device is cleared but with restricted indications
SE Post-Market Surveillance Required (SESP)	Substantially Equivalent with post-market study	Cleared, but manufacturer must conduct post-market study
SE Subject to Tracking (ST)	Substantially Equivalent with tracking requirements	Cleared, but subject to device tracking
NSE	Not Substantially Equivalent	Device may not be marketed; may submit as De Novo or PMA
Withdrawn	Submitter withdrew the 510(k)	No decision on equivalence

The K-Number System

Every 510(k) submission receives a unique control number called a "K-number." The format is:

K[YY][NNNN]

K = constant prefix
YY = two-digit calendar year (e.g., 26 for 2026)
NNNN = sequential submission number (0001, 0002, etc.)

For example, K260001 is the first 510(k) received by FDA in calendar year 2026. The K-number is assigned when FDA receives the submission, not when it makes a decision.

510(k) Review Timelines: What the Data Actually Shows

FDA's Stated Goal vs. Reality

FDA's performance goal under MDUFA V is to make a decision on 90% of 510(k)s within 90 FDA days. "FDA days" are calendar days minus any days the submission was on hold for an Additional Information (AI) request.

But the practical timeline tells a different story:

Metric	Value
FDA performance goal	90 FDA days
Average actual review time (2010–2021 data, ~25,000 submissions)	~164 FDA days
Current average calendar time to clearance (2025 data)	140–175 days
Submissions exceeding 90-day target	70–80%
Average review cycles per submission	~1.58
Percentage of submissions receiving at least one AI request	Majority

The Review Phase Timeline

The structured review process follows these phases:

Phase	Target Duration	What Happens
Receipt and Assignment	Day 0	FDA receives submission, assigns K-number
Acceptance Review	≤15 calendar days	FDA checks minimum completeness
RTA Hold (if applicable)	Up to 180 days to respond	Submitting must address completeness deficiencies
Substantive Review	≤60 FDA days	Lead reviewer evaluates technical content
Substantive Interaction	By Day 60	FDA communicates concerns or status
Additional Information Request	Clock stops	Submitter has 180 calendar days to respond
Final Decision	≤90 FDA days total	SE or NSE letter issued

Factors That Affect Clearance Time

Analysis of clearance data reveals several factors that significantly influence how long review takes:

Device complexity and novelty. Devices with novel technological characteristics or new intended uses take longer because reviewers must evaluate whether differences from the predicate raise new safety questions.

Submission quality. Complete, well-organized submissions with clear predicate comparisons, comprehensive testing data, and thorough risk analysis clear faster. Submissions with gaps trigger AI requests that add months.

Review division workload. FDA's review divisions have different workloads. High-volume divisions like Cardiovascular and Orthopedic may have longer queues.

Staffing levels. FDA's CDRH, which reported 2,260 staff and over 20,700 submissions processed in 2024, has since experienced significant workforce reductions — an estimated 22% of CDRH positions were eliminated between late 2024 and early 2026, reducing staff to approximately 1,800. While data as of mid-2026 does not yet show systematic delays attributable to these staffing changes, manufacturers should build additional buffer time into regulatory timelines.

Type of 510(k). Special 510(k)s have a 30-day review target and generally clear faster. Traditional and Abbreviated 510(k)s both target 90 FDA days but may differ in practice based on the content requirements.

Clearance Rates by Year

While specific year-by-year clearance rates fluctuate, the overall pattern is:

Approximately 85–90% of 510(k) submissions that reach a decision receive an SE finding
NSE rates are higher for first-time submitters and for devices in novel technology categories
Submissions that receive multiple AI requests have lower ultimate clearance rates

How to Track and Monitor 510(k) Clearances

FDA's 510(k) Database

The primary resource is FDA's publicly accessible 510(k) database at accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm.

You can search by:

510(k) number — Look up a specific submission
Applicant name — Find all clearances by a specific company
Device name — Search by device type
Product code — Find all clearances for a specific device category
Decision date range — Filter by when decisions were made
Panel — Filter by medical specialty panel (Cardiovascular, Orthopedic, etc.)
Type — Traditional, Special, or Abbreviated 510(k)
Third-party reviewed — Whether a third-party review organization performed the review
PCCP Authorized — Whether the device has a predetermined change control plan for AI/ML

Reading a 510(k) Record

Each 510(k) record contains:

Field	What It Tells You
510(k) Number	Unique identifier; year prefix tells you when it was submitted
Applicant	The company that submitted the 510(k)
Device Name	The proprietary or common name of the device
Product Code	The FDA product classification code
Date Received	When FDA received the submission
Decision Date	When FDA made the SE/NSE decision
Decision	SE, NSE, or other outcome code
Panel	The medical specialty panel that reviewed the device
Type	Traditional, Special, or Abbreviated

Accessing Clearance Letters and Supporting Documents

For many 510(k) clearances, you can access:

Summary of Safety and Effectiveness — A public summary of the data that supported the clearance decision. This is the most useful document for understanding what evidence FDA required.
510(k) clearance letter — FDA's formal decision letter
FOIA-redacted submissions — Some 510(k) submissions are available through FOIA requests with proprietary information redacted

FDA also publishes lists of cleared 510(k) submissions with supporting documents organized by year. For 2026, this list is updated regularly and can be found on FDA's website.

Using the openFDA API

For programmatic access to 510(k) data, FDA provides the openFDA API, which allows querying 510(k) records in bulk. This is useful for:

Tracking clearance trends for specific product codes
Building competitive intelligence databases
Analyzing review time patterns
Identifying predicate devices used by competitors

The API endpoint is: https://api.fda.gov/device/510k.json

You can query by product code, applicant, decision date, and other fields. Results include K-number, applicant, device name, decision date, and product code.

Commercial Intelligence from Clearance Data

Strategic uses of clearance data include:

Predicate selection. Search for the product code of your intended device to find all cleared predicates. Review the summary documents to understand what evidence supported clearance.

Competitive landscape. Search by competitor names to see what devices they have cleared, when, and using which predicates.

Timeline benchmarking. Calculate the gap between "date received" and "decision date" for your device category to estimate realistic clearance timelines.

Division workload assessment. Count the number of clearances per panel per year to gauge division throughput and potential queue length.

What Triggers an NSE Decision

Understanding why FDA issues NSE findings helps you avoid common pitfalls. The most frequent reasons include:

Inadequate Predicate Comparison

FDA expects a detailed, element-by-element comparison of technological characteristics. Submissions that assert equivalence without demonstrating it — especially when there are technological differences — receive NSE decisions.

New Technological Characteristics Raising New Questions

If your device has different technological characteristics from the predicate and those differences raise new types of safety or effectiveness questions, a 510(k) may not be the appropriate pathway. FDA may recommend the De Novo pathway instead.

Insufficient Performance Data

When technological characteristics differ, performance testing must demonstrate that the new device is as safe and effective as the predicate. Submissions with incomplete or inadequate testing data are a leading cause of NSE decisions.

Labeling and Intended Use Discrepancies

If the proposed indications for use differ materially from the predicate's indications, FDA may find the devices not substantially equivalent. This is particularly common when manufacturers try to expand the intended use beyond what the predicate supports.

Special Situations in 510(k) Clearances

PCCP-Authorized Clearances

FDA now indicates in the 510(k) database when a device has an authorized Predetermined Change Control Plan (PCCP). PCCPs allow manufacturers of AI/ML-enabled devices to make specified modifications without submitting a new 510(k) for each change. As of 2026, this field is searchable in the database.

Third-Party Reviewed 510(k)s

FDA's Third-Party Review Program allows accredited third-party review organizations to review eligible 510(k) submissions. The 510(k) database indicates which submissions were third-party reviewed. Third-party review can accelerate timelines for eligible devices.

510(k) Clearances with Post-Market Requirements

Some clearances include conditions that the manufacturer must fulfill after marketing:

Post-market surveillance studies (522 studies)
Device tracking requirements
Limitations on indications that restrict the cleared use

These conditions are noted in the decision letter and in the database with specific decision codes (SESP, ST, SESU).

2026 Factors Affecting Clearance Timelines

QMSR Implementation

Since February 2, 2026, all medical device manufacturers must comply with FDA's Quality Management System Regulation (QMSR), which incorporates ISO 13485:2016 by reference. This affects 510(k) submissions because the quality system information in submissions must align with QMSR requirements.

eSTAR Mandate

The eSTAR template is now mandatory for 510(k) submissions to CDRH. FDA expects eSTAR-formatted submissions to have lower RTA rates because the structured template helps submitters include all required content.

FY 2026 Guidance Agenda

FDA's CDRH has published several draft guidances that may affect 510(k) submissions when finalized:

Best Practices for Selecting a Predicate Device — Guidance on predicate selection methodology
Evidentiary Expectations for 510(k) Implant Devices — Higher evidence expectations for implantable devices
Recommendations for the Use of Clinical Data in 510(k) Submissions — When clinical data is expected
Substantial Equivalence with Limitations — Framework for clearances with restricted indications

FDA Staffing Considerations

Reports of staffing changes at CDRH in early 2026 have raised questions about future review capacity. As of mid-2026, available data does not yet show systematic delays attributable to staffing reductions, but manufacturers should build additional buffer time into launch timelines as a precautionary measure.

Practical Strategies for Faster Clearance

Pre-Submission Engagement

FDA's Q-Submission (Q-Sub) program allows manufacturers to request feedback before submitting a 510(k). A well-timed Q-Sub can:

Confirm your predicate selection
Align on testing expectations
Identify potential review issues early
Reduce the likelihood of AI requests during review

Comprehensive Submission Preparation

The data shows that submissions receiving AI requests take substantially longer. To minimize AI requests:

Include all testing required by applicable guidance documents and special controls
Provide complete predicate comparison tables
Include comprehensive risk analysis aligned with ISO 14971
Ensure software documentation meets IEC 62304 requirements
Address cybersecurity requirements per FDA's premarket cybersecurity guidance

Use Special 510(k) When Eligible

If you are modifying your own legally marketed device and the changes can be evaluated through design control procedures, a Special 510(k) may be appropriate. Special 510(k)s have a 30-day review target and typically clear much faster than traditional submissions.

Key Takeaways

Track your device category's clearance data before submitting. The 510(k) database reveals how long review takes for your product code, what predicates competitors used, and what success rates look like.
Plan for 4–9 months, not 90 days. The 90-day goal measures FDA review time excluding holds. Calendar time is almost always longer, and AI requests are common.
Read the Summary documents from competitor clearances. These reveal exactly what evidence FDA required for similar devices, helping you anticipate what your submission needs.
Use pre-submission meetings to reduce uncertainty. A Q-Sub before your 510(k) can align expectations on predicates, testing, and evidence requirements, reducing the chance of AI requests.
Monitor 2026 guidance developments. FDA's FY 2026 guidance agenda includes several documents that could change 510(k) expectations, particularly for implant devices and clinical data requirements.

Sources

FDA, "Premarket Notification 510(k)," current as of 2026
FDA, "510(k) Submission Process," current as of 2026
FDA, "Cleared 510(k) Submissions with Supporting Documents – 2026," updated May 28, 2026
FDA, "CDRH Proposed Guidances for Fiscal Year 2026 (FY2026)"
Emergo by UL, "Official outline of FDA 510(k) review process for medical devices"
The FDA Group, "What FDA Staffing Challenges Mean for Your 510(k) in 2026"
The FDA Group, "FDA 510(k) Explained: A Basic Guide to Premarket Notification," November 2025
MD+DI, "Factors Influencing FDA Clearance Time for Medical Devices," 2025
Complizen, "How Long Can FDA Approval Take? Understanding Timelines for Different FDA Pathways"
Intuition Labs, "FDA 510(k) Explained: Medical Device Premarket Notification Process"
Hogan Lovells, "FDA Device Guidance Agenda: What to Watch in 2026"